BioNexus Gene Lab Corp Files 2022 Annual Report Amendment
Ticker: BGLC · Form: 10-K/A · Filed: May 31, 2024 · CIK: 1737523
| Field | Detail |
|---|---|
| Company | Bionexus Gene Lab CORP (BGLC) |
| Form Type | 10-K/A |
| Filed Date | May 31, 2024 |
| Risk Level | low |
| Pages | 6 |
| Reading Time | 7 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: amendment, annual-report, medical-laboratories
TL;DR
BioNexus Gene Lab Corp filed its 2022 10-K amendment on 5/31/24. Check for updates.
AI Summary
BioNexus Gene Lab Corp filed an amendment (10-K/A) on May 31, 2024, for its fiscal year ending December 31, 2022. The company, incorporated in Wyoming, operates in the medical laboratories sector. Its principal business address is in Kuala Lumpur, Malaysia.
Why It Matters
This filing provides updated information for the fiscal year 2022, which is crucial for investors to assess the company's financial health and operational status.
Risk Assessment
Risk Level: low — This is a routine amendment to a previously filed annual report, not indicating new material adverse events.
Key Numbers
- 2022-12-31 — Fiscal Year End (The period covered by the annual report.)
- 2024-05-31 — Filing Date (The date the amendment was submitted to the SEC.)
Key Players & Entities
- BioNexus Gene Lab Corp (company) — Registrant
- Wyoming (jurisdiction) — State of Incorporation
- Kuala Lumpur (location) — Business Address City
- 001-41750 (identifier) — Commission File Number
- 20221231 (date) — Fiscal Year End
- 20240531 (date) — Filing Date
FAQ
What is the primary purpose of this 10-K/A filing?
This filing is an amendment to the Annual Report on Form 10-K for the fiscal year ended December 31, 2022, indicating updates or corrections to the original filing.
When was the original fiscal year end for this report?
The original fiscal year end for this report was December 31, 2022.
What is the company's state of incorporation?
The company, BioNexus Gene Lab Corp, is incorporated in Wyoming.
Where is BioNexus Gene Lab Corp's business located?
The company's business address is located in Kuala Lumpur, Malaysia.
What is the SEC file number for BioNexus Gene Lab Corp?
The Commission File Number for BioNexus Gene Lab Corp is 001-41750.
Filing Stats: 1,714 words · 7 min read · ~6 pages · Grade level 16.2 · Accepted 2024-05-31 15:45:21
Filing Documents
- bglc_10ka.htm (10-K/A) — 46KB
- bglc_ex311.htm (EX-31.1) — 10KB
- 0001477932-24-003418.txt ( ) — 237KB
- bglc-20221231.xsd (EX-101.SCH) — 6KB
- bglc-20221231_lab.xml (EX-101.LAB) — 22KB
- bglc-20221231_cal.xml (EX-101.CAL) — 1KB
- bglc-20221231_pre.xml (EX-101.PRE) — 14KB
- bglc-20221231_def.xml (EX-101.DEF) — 2KB
- bglc_10ka_htm.xml (XML) — 6KB
Controls and Procedures
Item 9A. Controls and Procedures. Evaluation of Disclosure Controls and Procedures In connection with the preparation of this annual report, an evaluation was carried out by the Company's management, with the participation of the principal executive officer and the principal financial officer, of the effectiveness of the Company's disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act ("Exchange Act") as of December 31, 2022. Disclosure controls and procedures are designed to ensure that information required to be disclosed in reports filed or submitted under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the Commission's rules and forms, and that such information is accumulated and communicated to management, including the principal executive officer and the principal financial officer, to allow timely decisions regarding required disclosures. Based on that evaluation, the Company's management concluded, as of the end of the period covered by this report, that the Company's disclosure controls and procedures were not effective in recording, processing, summarizing, and reporting information required to be disclosed, within the time periods specified in the Commission's rules and forms, and that such information was not accumulated and communicated to management, including the principal executive officer and the principal financial officer, to allow timely decisions regarding required disclosures. The Company's disclosure controls and procedures were not effective due to the fact that the Part II., Item 9A Controls and Procedures in the Original Filing were inaccurate. Management's Report on Internal Control over Financial Reporting The management of the Company is responsible for establishing and maintaining adequate internal control over financial reporting. The Company's internal control over financial reporting is a process, under the supervision of t
Exhibits
Item 6. Exhibits. Exhibit Description 31.1 Certification of the Company's Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 104 Cover Page Interactive Data File (embedded within the Inline XBRL Document) 4
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. BIONEXUS GENE LAB CORPORATION /s/ Su-Leng Tan Lee Su-Leng Tan Lee Chief Executive Officer (Principal Executive Officer) /s/ Su-Leng Tan Lee Su-Leng Tan Lee Acting Chief Financial Officer (Acting Principal Financial and Accounting Officer) May 31, 2024 5